Entries by CoratTx

COR-101 approved for first clinical study

CORAT Therapeutics GmbH obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101. The study (ClinicalTrials.gov ID: NCT04674566) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter, first-in-human, phase Ib/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of COR-101 in hospitalized patients with moderate to severe COVID-19. We […]

Second financing round secured for the development of COR-101

A second financing round was closed with NBank Capital, the investment company of NBank. Additional investors came from the private sector in Braunschweig. CORAT Therapeutics is in close coordination with the regulatory authorities and expects the green light for the start of clinical testing shortly. “The development of a drug against Corona must not fail […]

Human SARS-CoV-2 neutralizing antibody COR-101 demonstrates high efficacy in a COVID-19 animal model and is ready to be used in clinical studies to treat COVID-19 patients

COR-101 decreased SARS-CoV-2 virus load in the lung by more than 99% COR-101 induced recovery after 2 days, compared to 7 days untreated CORAT Therapeutics GmbH today reports the successful conclusion of hamster disease model tests of their lead candidate COR-101 against COVID-19. It induced recovery of SARS-CoV-2 infected hamsters within two days. In contrast, […]

How human antibody COR-101 neutralizes the coronavirus SARS-CoV-2

Because SARS-CoV-2 is a novel virus, many people have not yet developed antibodies against the pathogen. Vaccines can protect healthy people, but they cannot cure people affected by COVID-19. Furthermore, not everyone responds to the vaccine. Passive immunisation by administering antibodies can help here for both, curing those people affected and prevent infection and/or onset […]

CORAT won the Durchstarter Award of the State of Lower Saxony

In an event with Economics Minister Dr. Althusmann, Dr. Sabine Johannsen, State Secretary for Science and Culture and Stefan Muhle, State Secretary in Lower Saxony’s Ministry of Economics, Labour, Transport and Digitisation, CORAT Therapeutics won this year’s startup Award „Durchstarterpreis“ for corona solutions of the State of Lower Saxony. Worldwide, hundreds of millions of people […]

CORAT lead product COR-101 ready for clinical trials

15.11.2020 – CORAT Therapeutics CEO Dr. Andreas Herrmann today proudly reports the conclusion of the production campaign providing the first larger batch of COR-101 ready for the patients. COR-101 is a fully human antibody developed in Braunschweig which efficiently blocks the cell entry of the SARS-CoV-2, thereby preventing infection with the  Coronavirus. Because COR-101 directly […]

CORAT won the Innovation Award of the State of Lower Saxony

Lower Saxony’s Minister of Economics Dr. Bernd Althusmann and Lower Saxony’s Minister of Science Björn Thümler, together with Prof. Josef von Helden, Chairman of the Board of the Innovation Network Lower Saxony, once again honoured visionary ideas, cooperation stories and economic successes from Lower Saxony with the Lower Saxony Innovation Award on 28.9.2020. This year, […]

CORAT Therapeutics founded

With support from the German Federal State of Lower Saxony, CORAT Therpeutics was formed as a dedicated body to promote the further development of the antibody based COVID-10 medicine. “What is being developed here in Braunschweig may save lives all over the world. Therefore, we decided to provide CORAT Therapeutics a financial base for the […]

Fully neutralising antibodies to SARS-CoV-2

CORAT generated fully neutralising coronavirus antibodies protecting against SARS-CoV-2 infection, as confirmed by the Helmholtz Center for Infection Research “This result represents a crucial milestone in development of an effective therapy for Covid-19.” (Dr. Thomas Schirrmann) Promising candidate for Covid-19 antibody therapy (PDF, english)Vielversprechender Wirkstoffkandidat zur Behandlung von Covid-19  (PDF, german)